Gilead Sciences, Inc. which can be found using ticker (GILD) have now 25 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $117.00 and $67.00 suggesting an average analyst share price target price of $81.21. (at the time of writing). Given that the stocks previous close was at $63.15 this now indicates there is a potential upside of 28.6%. There is a 50 day moving average of $65.84 and the 200 day MA is $74.08. The company has a market cap of 85.33B. The stock price is currently at: $68.49 USD
The potential market cap would be $109,730,932,988 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 190.25, revenue per share of $22.00 and a 10.5% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
